Comprehensive Genomic and Transcriptomic Analysis for Guiding Therapeutic Decisions in Patients with Rare CancersPeter Horak, Klaus Schulze‐Osthoff, Martina Fröhlich et al.|Cancer Discovery|2021Cited by 282
Secondary-type mutations do not impact outcome in NPM1-mutated acute myeloid leukemia – implications for the European LeukemiaNet risk classificationJan‐Niklas Eckardt, Christoph Röllig, Marius Bill et al.|Leukemia|2023Cited by 36
Validation of the revised 2022 European LeukemiaNet risk stratification in adult patients with acute myeloid leukemiaLeo Ruhnke, Christoph Röllig, Marius Bill et al.|Blood Advances|2024Cited by 17